N. Herold, S. G. Rudd, L. Ljungblad, K. Sanjiv, C.B.J. Paulin, I. Hed Myrberg, A. Hagenkort , J. Kutzner , J. M. Calderón-Montaño, B. D. G. Page, O. Loseva, A. S. Jemth , L. Bulli, H. Axelsson, G. Rassidakis, M. Heyman, K. Pokrovskaja Thamm, D. Grandér, T. Lundbäck, P. Kogner, J. I. Henter, T. Helleday, T. Schaller: Targeting SAMHD1 with Vpx as a Strategy to Improve Cytarabine Therapy. Nat. Med. 2017, 23, 256-263 .

N. C.K. Valerie, A. Hagenkort, B. D. G. Page, G. Masuyer, D. Rehling, M. Carter, L. Bevc, P. Herr, E. Homan, N. G. Sheppard, P. Stenmark, A. S. Jemth T. Helleday: NUDT15 mediates the cellular efficacy of 6-thioguanine by hydrolyzing 6-thio-(d)GTP. Cancer Res. 76 (18), 5501-5511. 

A. Belton, L. Xian, T. Huso, M. Koo, L. Luo, J. Turkson, B. D. G. Page, P. T. Gunning, G. Liu,  D. L. Huso, L. M. S. Resar: STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway. Leuk. Lymphoma. 2016, 57 (11), 2681-2684. 

C. C. Arpin, S. Mac, Y. Jiang, H. Cheng, M. Grimard, B. D. G. Page, M. M. Kamocka, S. Haftchenary, H. Su, D. Ball, D. A. Rosa, P. S. Lai, R. F. Gomez-Biagi, A. M. Ali, R. Rana, H. Hanenberg, K. Kerman, K. C. McElyea, G. E. Sandusky, P. T. Gunning, M. L. Fishel: Applying Small Molecule Signal Transducer and Activator of Trancription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Mol. Cancer Ther. 2016, 15 (5) 794-805. 

B. D. G. Page, M. Carter, A. S. Jemth, A. Hagenkort, R. Gustafsson, J. J. Griese, H. Gad, N. C. K. Valerie, M. Desroses, U. W. Berglund, T. Helleday, P. Stenmark. The structure and function of NUDT15 (MTH2) are distinct from MTH1. Nat. Commun. 2015, 6, 7871.


M. Singh, N. Garg, C. Venugopal, R. Hallett, T. Tokar, N. McFarlane, S. Mahendram, D. Bakhshinyan, P. Vora, B. Manoranjan, M. Qazi, D. Rosa, C. C. Arpin, B. D. G. Page, S. Haftchenary, A. Todic, P. S. Lai, R. Gómez-Biagi, A. Ali, A. Lewis, M. Geletu, N. Murty, J. Hassell, I. Jurisica, P. T. Gunning, S. Singh: STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget, 2015, 6 (29), 27461.

B. D. G. Page, A. M. Eiring, I. L. Kraft, A. Senina, A. D. Pomicter, D. J. Anderson, T. Y. Zhang, Z. Gu, J. S. Khorashad, K. R. Reynolds, M. S. Zabriskie, R. Moriggl, T. O’Hare, P. T. Gunning, M. W. Deininger: Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia. Leukemia. 2015, 29, 586-597. 

M. A. Telpoukhovskaia, J. F. Cawthray, C. Rodríguez-Rodríguez, L. E. Scott, B. D. G. Page, B. O. Patrick, C. Orvig:  3-Hydroxy-4-pyridinone Derivatives Designed for Fluorescence Studies to Determine Interaction with Amyloid Protein as well as Cell Permeability.  Bioorg. Med. Chem. Lett. 2015, 25 (7), 3654-3657.

A. Z. Lai, S. Cory, H. Zhao, M. Gigoux, A. Monast, M. Guiot, S. Huang, A. Tofigh, C. Thompson, M. Naujokas, V. A. Marcus, N. Bertos, B. Sehat, R. M. Perera, E. S. Bell, B. D. G. Page, P. T. Gunning, L. E. Ferri, M. Hallett, M. Park: Dynamic Reprogramming of Signaling upon Met Inhibition Reveals Pathways for Cell Proliferation and Negative Feedback in Gastric Cancer. Sci. Signal. 2014, 7 (322), ra38. 

M. A. Telpoukhovskaia, C. Rodríguez-Rodríguez, L. E. Scott, B. D. G. Page, B. O. Patrick, C. Orvig: Synthesis, Characterization, and Cytotoxicity Studies of Cu(II), Zn(II), and Fe(III) Complexes of N-derivatized 3-hydroxy-4-pyridiones. J. Inorg. Biochem. 2014, 132, 59-66. 

M. A. Telpoukhovskaia, C. Rodríguez-Rodríguez, J. F. Cawthray, L. E. Scott, B. D. G. Page, J. Alí-Torres, M. Sodupe, G. A. Bailey, B. O. Patrick, C. Orvig: 3-Hydroxy-4-pyridinone Derivatives as Metal Ion and Amyloid Binding Agents. Metallomics 2014, 6, 249-262. 

See the full list via Google Scholar or LinkedIn 

  • Google+ - Grey Circle
  • LinkedIn Clean Grey